Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription

A Muir, A Peck, M Clare-Salzler, Y H Song, J Cornelius, R Luchetta, J Krischer, N Maclaren, A Muir, A Peck, M Clare-Salzler, Y H Song, J Cornelius, R Luchetta, J Krischer, N Maclaren

Abstract

We reported previously that daily injections of isophane insulin prevented both hyperglycemia and insulitis in nonobese diabetic (NOD) mice (Atkinson, M., N. Maclaren; and R. Luchetta. 1990. Diabetes. 39:933-937). The possible mechanisms responsible include reduced immunogenicity of pancreatic beta-cells from "beta-cell rest" and induced active immunoregulation to insulin (Aaen, IK., J. Rygaard, K. Josefsen, H. Petersen, C. H. Brogren, T. Horn, and K. Buschard. 1990. Diabetes. 39:697-701). We report here that intermittent immunizations with insulin or its metabolically inactive B-chain in incomplete Freund's adjuvant also prevent diabetes in NOD mice, whereas immunizations with A-chain insulin or with BSA do not. Adoptive transfer of splenocytes from B-chain insulin-immunized mice prevented diabetes in recipients co-infused with diabetogenic spleen cells, an effect that was abolished by prior in vivo elimination of either CD4+ or CD8+ cells. Insulin immunization did not reduce the extent of intraislet inflammation (insulitis); however, it did abolish expression of IFN-gamma mRNA within the insulitis lesions. Immunizations with insulin thus induce an active suppressive response to determinants on the B-chain that converts the insulitis lesion from one that is destructive to one that is protective.

References

    1. Diabetes. 1990 Aug;39(8):933-7
    1. Diabetes Metab Rev. 1993 Dec;9(4):279-87
    1. J Immunol Methods. 1973 Oct;3(2):147-63
    1. Science. 1983 Dec 23;222(4630):1337-9
    1. Nature. 1984 Dec 6-12;312(5994):548-51
    1. Diabetologia. 1985 Dec;28(12):933-5
    1. Eur J Immunol. 1987 Aug;17(8):1159-65
    1. J Immunol. 1988 Oct 1;141(7):2325-9
    1. J Immunol. 1989 Feb 1;142(3):748-52
    1. Clin Immunol Immunopathol. 1989 Apr;51(1):38-54
    1. J Exp Med. 1989 May 1;169(5):1669-80
    1. Diabetes. 1989 Dec;38(12):1647-51
    1. J Autoimmun. 1989 Dec;2(6):759-76
    1. Diabetes. 1990 May;39(5):583-9
    1. Diabetes. 1990 Jun;39(6):697-701
    1. J Clin Endocrinol Metab. 1990 Jul;71(1):152-6
    1. Nature. 1990 Aug 30;346(6287):844-7
    1. Mol Biol Med. 1990 Aug;7(4):333-9
    1. J Clin Invest. 1991 Feb;87(2):739-42
    1. J Immunol. 1991 Feb 15;146(4):1163-8
    1. Immunol Today. 1990 Nov;11(11):383-6
    1. Eur J Immunol. 1991 Apr;21(4):873-9
    1. J Pathol. 1991 Oct;165(2):97-103
    1. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421-5
    1. J Exp Med. 1992 Nov 1;176(5):1355-64
    1. Lancet. 1993 Apr 10;341(8850):927-8
    1. J Autoimmun. 1993 Jun;6(3):291-300
    1. J Clin Invest. 1993 Oct;92(4):1608-16
    1. J Immunol. 1993 Oct 15;151(8):4362-70
    1. Autoimmunity. 1993;15(2):113-22
    1. Nature. 1993 Nov 4;366(6450):72-5
    1. Lancet. 1994 Mar 19;343(8899):704-6
    1. Lancet. 1994 Mar 19;343(8899):706-7
    1. J Exp Med. 1994 Apr 1;179(4):1379-84
    1. Clin Immunol Immunopathol. 1994 May;71(2):169-75
    1. Autoimmunity. 1993;16(3):181-8
    1. Cancer Chemother Rep. 1966 Mar;50(3):163-70

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere